🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Tenet Healthcare Corporation THC R3KPHARMA

Healthcare · Medical Care Facilities · United States
https://www.tenethealth.com
Company Profile ↓
$259.06
+50.73% 1Y
Mkt Cap$20.86B
P/E10.01
P/B4.53
52W High$280.77
52W Low$161.37
Book Value$57.86
EPS (TTM)$25.88

Company Overview

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient services, including physical therapy; tertiary care services, such as cardiothoracic surgery, complex spinal surgery, neonatal intensive care, and neurosurgery services; pediatric quaternary care services through heart, liver, and kidney transplants programs; and limb salvaging vascular procedure, acute level 1 trauma, intravascular stroke care, minimally invasive cardiac valve replacement, imaging technology, surgical robotic, and telemedicine access services. In addition, it offers a range of procedures and services comprising orthopedics, total joint replacement, and spinal and other musculoskeletal procedures; gastroenterology; pain management; otolaryngology; ophthalmology; and urology. Further, the company operates acute care and specialty hospitals, off-campus emergency departments, imaging centers, urgent care centers, and micro-hospitals, as well as ambulatory surgery centers and surgical hospitals. Tenet Healthcare Corporation was founded in 1967 and is headquartered in Dallas, Texas.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 37.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 28.6% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 10.0, below the sector median of 24.8.

Healthy Margins

Operating margin of 18.2% supports profitability.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $21.31B (+3.1% YoY); net profit $1.41B.
  • Trailing 12 Months Year-on-year growth — revenue +6.8%, earnings +213.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 0.1%, profit CAGR 28.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:0.14%
1 Year:6.80%

Compounded Profit Growth

5 Years:28.65%
1 Year:213.40%

Stock Price Performance

1 Year:+50.73%
6 Months:+7.68%
3 Months:+58.92%
1 Month:-1.17%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 82% of range
$161.37 $280.77
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)50.62 · Neutral
Price Performance
1M-1.17%
3M+58.92%
6M+7.68%
1Y+50.73%
Valuation vs Sector

P/E of 10.01 is below the sector median of 24.83 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 37.3%.
  • Profit CAGR of 28.6% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
10.01
Industry PE
24.83
Forward P/E
12.29
PEG Ratio
1.84
Book Value
$57.86
Price to Book
4.53
P/S
0.97
EV/EBITDA
7.47
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
0.14%
Profit 5Y
28.65%
Revenue (YoY)
6.80%
Earnings (YoY)
213.40%

Profitability & Returns

ROCE
13.64%
ROE
37.34%
ROA
8.32%
Profit Margin
10.27%
Op Margin
18.16%
Gross Margin
41.66%
EPS (Latest Qtr)
$9.84
EPS (TTM)
$25.88

Balance Sheet & Liquidity

Debt/Equity
1.52
Quick Ratio
1.15
Current Ratio
1.41
Debt
$13.25B
Total Assets
$30.68B
Current Assets
$7.83B
Working Capital
$3.39B

Ownership

Promoter Holding
0.97%
Chg in Prom Hold
-0.03%
FII / Inst Holding
101.92%
Chg in FII Hold
-0.50%

Financial Snapshot

Enterprise Value
$20.86B
Total Revenue (TTM)
$21.81B
EBITDA
$4.84B
Free Cash Flow
$2.25B
Operating Cash Flow
$4.02B
Shares Outstanding
80.52M
Gross Margin
41.66%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 THC Tenet Healthcare Corporation R3KPHARMA 259.06 10.01 $20.86B 0.00% 13.64% 37.34% 0.14% 28.65%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -------5.17B4.94B-----4.54B4.56B4.57B4.81B4.52B3.65B4.56B4.92B4.78B4.95B4.89B4.75B4.64B4.80B5.02B5.08B5.07B5.37B5.11B5.13B-5.27B5.29B5.53B5.78B6.04B
Cost of Revenue -----------------------------------932.00M931.00M1.01B961.00M984.00M
Gross Profit -----------------------------------4.34B4.36B4.52B4.82B5.06B
Operating Expenses -----------------------------------3.49B3.54B3.65B3.52B3.62B
Operating Income 290.00M164.00M287.00M354.00M274.00M339.00M267.00M310.00M51.00M-517.00M406.00M320.00M-381.00M400.00M302.00M-327.00M471.00M271.00M-520.00M586.00M1.01B648.00M553.00M596.00M603.00M604.00M568.00M3.29B761.00M1.09B-852.00M817.00M869.00M1.29B1.44B
EBITDA -----------------------------------1.06B1.14B1.12B1.57B1.76B
Interest Expense -----------------------------------206.00M206.00M205.00M205.00M204.00M
Pretax Income -----------------------------------642.00M712.00M681.00M1.13B1.34B
Tax Provision -----------------------------------120.00M133.00M37.00M226.00M295.00M
Net Income -----------------------------------288.00M342.00M371.00M702.00M826.00M
Diluted EPS 0.47-0.61-0.29-0.60-0.46-0.08-0.53-0.55-3.64-2.270.960.25-0.09-0.04-0.110.25-2.18-0.030.880.83-1.863.860.901.104.131.280.351.161.321.150.9421.382.644.89-3.143.864.228.019.84

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------21.07B20.61B18.31B18.48B17.64B-19.17B20.56B20.68B21.31B
Cost of Revenue --------------3.27B3.59B3.65B3.78B
Gross Profit --------------15.90B16.97B17.03B17.53B
Operating Expenses --------------13.49B14.53B14.11B14.09B
Operating Income 311.00M538.00M634.00M653.00M749.00M663.00M925.00M1.08B1.25B1.11B1.64B1.54B1.99B-2.41B2.44B2.92B3.44B
EBITDA --------------3.08B3.39B6.89B4.48B
Interest Expense --------------890.00M901.00M826.00M821.00M
Pretax Income --------------1.34B1.62B5.25B2.80B
Tax Provision --------------344.00M306.00M1.18B433.00M
Net Income 25.00M181.00M1.12B58.00M141.00M-134.00M12.00M-140.00M-192.00M-704.00M104.00M-215.00M399.00M-411.00M611.00M3.20B1.41B
Diluted EPS 0.050.378.160.481.30-1.320.12-1.41-1.93-7.001.00-2.083.75-3.795.7132.7015.49

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --7.95B8.50B8.46B9.04B16.45B17.95B23.68B24.70B23.39B22.43B23.36B27.11B-27.16B28.31B28.94B29.68B
Current Assets ---------------5.98B7.17B7.68B7.85B
Cash & Equivalents 572.00M507.00M690.00M405.00M113.00M364.00M113.00M193.00M356.00M716.00M611.00M411.00M262.00M2.45B-858.00M1.23B3.02B2.88B
Inventory ---------------405.00M411.00M346.00M348.00M
Receivables ---------------2.94B2.91B2.54B2.56B
Total Liabilities --7.26B6.68B6.95B7.81B15.23B16.77B20.46B21.23B20.98B20.30B21.42B24.22B-22.55B22.80B20.39B20.70B
Current Liabilities --1.78B1.73B1.81B1.76B3.09B3.58B4.31B4.03B4.33B3.86B4.21B4.85B-4.48B4.76B4.31B4.46B
Long Term Debt ---------------14.93B14.88B13.08B13.09B
Total Debt ---------------15.08B15.00B13.17B13.17B
Total Equity 88.00M147.00M646.00M1.77B1.42B1.14B755.00M651.00M691.00M417.00M-147.00M-119.00M-417.00M28.00M-1.14B1.61B4.17B4.22B
Shares Outstanding ---------------156.46M157.27M158.00M158.61M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 208.00M425.00M472.00M497.00M593.00M589.00M687.00M1.03B558.00M1.20B1.05B1.23B3.41B-1.08B2.37B2.05B3.54B
Investing Cash Flow -274.00M-125.00M-420.00M-503.00M-662.00M-2.16B-1.32B-1.32B-430.00M21.00M-115.00M-619.00M-1.61B--808.00M-969.00M3.43B-1.27B
Financing Cash Flow 1.00M-117.00M-337.00M-286.00M320.00M1.32B715.00M454.00M232.00M-1.33B-1.13B-763.00M385.00M-936.00M-1.78B-1.03B-3.69B-
Capital Expenditure ----467.00M-506.00M-691.00M-933.00M-842.00M-875.00M-707.00M-617.00M-670.00M-540.00M--762.00M-751.00M-931.00M-1.01B
Free Cash Flow ---30.00M87.00M-102.00M-246.00M184.00M-317.00M493.00M432.00M563.00M2.87B-321.00M1.62B1.12B2.53B
Net Change in Cash ---------------1.51B370.00M1.79B-136.00M
Share Buybacks -00374.00M126.00M400.00M-40.00M00--00250.00M200.00M672.00M1.39B

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------82.9%82.5%82.4%82.3%
Operating Margin % --------5.9%5.4%8.9%8.3%11.3%-12.6%11.9%14.1%16.1%
Net Margin % ---------0.9%-3.4%0.6%-1.2%2.3%-2.1%3.0%15.5%6.6%
ROE % 17.0%28.0%63.4%4.1%12.3%-17.7%1.8%-20.3%-46.0%478.9%-87.4%51.6%1,425.0%-36.0%38.0%76.7%33.3%
ROCE % -8.7%9.4%9.8%10.3%5.0%6.4%5.6%6.0%5.8%8.8%8.0%8.9%-10.6%10.4%11.8%13.6%

Shareholding Pattern

Insiders
0.97%
Institutions
101.92%
Public Float
102.92%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 10.86% 8.74M $2.29B
2 Price (T.Rowe) Associates Inc 9.88% 7.96M $2.08B
3 Boston Partners 5.51% 4.43M $1.16B
4 Vanguard Portfolio Management LLC 5.26% 4.24M $1.11B
5 FMR, LLC 4.96% 3.99M $1.05B
6 Vanguard Capital Management LLC 4.84% 3.89M $1.02B
7 State Street Corporation 3.42% 2.75M $720.81M
8 Glenview Capital Management, Llc 2.78% 2.24M $585.72M
9 Geode Capital Management, LLC 2.34% 1.88M $493.85M
10 Citadel Advisors Llc 2.19% 1.77M $462.57M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for THC

Google News ue, 08 Sep 2026

Tenet could refinance $1.5B due in 2027 with notes due in 2034. - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQZ1ZFR2E2bnVhQnpOeGRWemR2WERpSm1BRFlscXB3VkpHcVhJR01IRnVlU09aTml0cWFfOTNqUl92U2ZiNVlNd2NDQ0FJQjdGWXgtaTZRWjdXRUhxdTVhNjRqUUlocGozVy1OZll3RC1aVkpINjFMZHhoQVh3NGtTenJieHlKNXo3Q0V3c1…

Google News Fri, 04 Sep 2026

Fast-paced Momentum Stock Tenet (THC) Is Still Trading at a Bargain - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPZXdPV1ZSR0pWMkxVQlA5bVB0SkptVWI2NkcxZmdqXzZxbWVXNy0wQUs0cU1Vei04Wkw4OEo0a3pBTjNKNUhIaVpiRVp0RTFFTXRtdUFJV2tibkZXU3BxS0p6Njh6ekdUdVV5TUZPb21nRXB4NXdENHdrdW9icElzY05KWE5taTdaT05EVG…

Google News Mon, 07 Sep 2026

Tenet Healthcare Corporation (THC) Stock Analysis: Unpacking The 7.56% Upside Potential - directorstalkinterviews.com

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQaGZkUUNRQm1waTJwOUJVaEI1MkNNckdfRTdRR0IxcklsWWpJNm1NMXNYcm45ZnNJQXd6QjNnX20tRHRldHlDc3VaWnh6ZlBFUUw4ODFJT0t0cWtUMnktdWhNMFJwZElCT05qcG9oRzRXemdWaXlESWR5NEg4dEFFN2Q5Z290ekF6T3pFZn…

Google News Sun, 23 Aug 2026

Tenet Healthcare (THC) Stock Jumped, What Is Behind The Fresh Attention? - simplywall.st

<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxNV0RuM3F5ajFUVnNHNkF4NVI0T1ozWVk4MTlVX3p5MFFNYjdUNEZRMURDQ0w3OXBILTR1ZEpQcV9XUFBsR2NVcGhORTI3RUFYNkVBVmw4eU4xd3poM1lrUk9ETFU5a2p2V0Q5UGJFVmZfNWRMaFh5czRoUGppMEdCQ2xFY1k4bEtodFJybT…

Google News ue, 08 Sep 2026

THC Looks 42.8% Overvalued on GF Value™ - gurufocus.com

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPTnlnV2tJc3Vjblh0VDlyV0JraV9SRjdLNVViSmF6dWZsU21idVlEUGd5WkxqQ3lwZ1llMGQtdm5uSmxveVRQWjF2T1lYNDZoVjlsZEZXT1FmRnBwUUl2RFdZcG4yU01wVHY4cUJqY0tBZHpDMGFxWW10WDdfWkdHTg?oc=5" target="_…

Google News Wed, 02 Sep 2026

THC - The CEO Sold $27.6 Million This Month, With the Stock at Records and Zacks Naming It a Strong Buy Today - kavout.com

<a href="https://news.google.com/rss/articles/CBMi3gFBVV95cUxQaXNJNWlENWdCeGxBaTE2TThmWGdCbzR0a29RVWpxbERUVE1EYTFLTG15SGJzdG85bXBral9wNmJGNVM2NlRPb0JLX3lnYmZuRVo2NWxNelhBYkdWUll6LUM4dkNab3I0Wng2TUMwSk43ZVhuUXQ4X2FnVlozdXJvbFhDRUVGWDk5QU5Zd1…

THC — Frequently Asked Questions

What is the current share price of Tenet Healthcare Corporation (THC)?

As of 2026-09-19 21:16 PDT, Tenet Healthcare Corporation (THC) trades at $259.06 on NYSE. Its 52-week range is $161.37 to $280.77.

What is the market capitalisation of THC?

Tenet Healthcare Corporation (THC) has a market capitalisation of $20.86B on NYSE.

What is the P/E ratio of THC?

THC trades at a trailing price-to-earnings (P/E) ratio of 10.01. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.53.

What is the return on equity (ROE) of THC?

THC has a return on equity (ROE) of 37.34%. Its return on capital employed (ROCE) is 13.64%.

Is THC a good stock to buy?

This page provides a data-driven analysis of Tenet Healthcare Corporation (THC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space